Phosphofructokinase

Phosphofructokinase
Name	Phosphofructokinase
Ec number	2.7.1.11
Width	260
Other names	PFK

Phosphofructokinase is a key metabolic enzyme catalyzing the phosphorylation of fructose 6‑phosphate to fructose 1,6‑bisphosphate, a rate‑controlling step in glycolysis. Discovered during early 20th‑century studies of carbohydrate metabolism, it has been the focus of research spanning enzymology, cell biology, and clinical medicine, influencing work at institutions such as Max Planck Society, Harvard University, and Johns Hopkins University. Its regulation integrates signals studied by researchers from University of Cambridge, Massachusetts Institute of Technology, and University of Oxford.

Structure and Isozymes

Phosphofructokinase exists as homo‑ or heterotetramers with quaternary architectures elucidated by laboratories at European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, and Stanford University. Mammalian forms include tissue‑specific isozymes encoded by distinct genes studied at National Institutes of Health and Wellcome Trust funded projects; skeletal muscle, liver, and platelet/erythrocyte variants exhibit different subunit compositions characterized by groups at University of California, Berkeley, Imperial College London, and Yale University. High‑resolution crystal structures deposited from work at Brookhaven National Laboratory and Argonne National Laboratory revealed active site residues and allosteric interfaces comparable to findings from teams at University of Tokyo and École Normale Supérieure. Structural comparisons link orthologs from Escherichia coli, Saccharomyces cerevisiae, and Arabidopsis thaliana to vertebrate isozymes, informing evolutionary studies by researchers affiliated with Smithsonian Institution and Natural History Museum, London.

Catalytic Mechanism and Regulation

The catalytic mechanism involves Mg2+‑dependent transfer of a phosphoryl group from ATP to sugar substrates, a reaction probed using methods from Max Planck Institute for Biophysical Chemistry and Rutherford Appleton Laboratory. Allosteric regulation by effectors such as ATP, ADP, AMP, and fructose 2,6‑bisphosphate has been dissected using kinetics approaches developed at University of Chicago and Washington University in St. Louis. Hormonal control—illustrated in studies by teams at University of California, San Francisco and Karolinska Institutet—links phosphofructokinase activity to signaling pathways investigated by researchers at Cold Spring Harbor Laboratory and Salk Institute. Conformational transitions between R and T states echo models from work at Pasteur Institute and Ludwig Maximilian University of Munich, while mutagenesis studies conducted at University of Toronto and John Innes Centre identified residues critical for cooperativity.

Role in Metabolism and Pathways

Phosphofructokinase occupies a central node in glycolysis and interfaces with gluconeogenesis, pentose phosphate pathway, and tricarboxylic acid cycle fluxes explored by consortia including European Bioinformatics Institute and Broad Institute. Its activity shapes metabolic reprogramming described in research at Memorial Sloan Kettering Cancer Center and Dana‑Farber Cancer Institute, and it affects cellular responses in studies from National Cancer Institute and Fred Hutchinson Cancer Center. Connections to hypoxia pathways analyzed at Karolinska Institutet and University of Pennsylvania link phosphofructokinase to transcriptional programs studied by teams at Cold Spring Harbor Laboratory and Howard Hughes Medical Institute.

Genetic and Evolutionary Aspects

Genes encoding phosphofructokinase subunits have been mapped and sequenced by projects at National Human Genome Research Institute and Genome Research Limited, revealing conservation across taxa examined at University of Sydney and University of Cape Town. Phylogenetic analyses from University of Edinburgh and University of Copenhagen suggest gene duplication and divergence events paralleling those reported in studies of metabolic gene families at Max Planck Institute for Evolutionary Anthropology. Comparative genomics initiatives at Joint Genome Institute and Ensembl trace isozyme diversification in vertebrates and plants, with population genetics investigations by groups at Wellcome Sanger Institute and Cold Spring Harbor Laboratory linking variants to adaptation.

Clinical Significance and Disorders

Inherited deficiencies of specific phosphofructokinase isozymes cause metabolic myopathies and hemolytic anemias characterized in clinical studies at Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital. Cancer‑associated changes in expression have been documented at Memorial Sloan Kettering Cancer Center and Dana‑Farber Cancer Institute, while metabolic syndrome and diabetes correlations emerged from epidemiological cohorts run by Framingham Heart Study and UK Biobank. Diagnostic assays and clinical guidelines from American College of Physicians and therapeutic explorations at National Institutes of Health and European Medicines Agency reflect translational interest.

Biotechnological and Research Applications

Phosphofructokinase is used in synthetic biology and metabolic engineering projects at MIT Media Lab, ETH Zurich, and University of California, San Diego to modulate glycolytic flux in microbial cell factories such as Saccharomyces cerevisiae and Escherichia coli. Assay platforms developed at Thermo Fisher Scientific and Agilent Technologies enable high‑throughput screening in drug discovery pipelines at Pfizer, Novartis, and Roche. Structural and mechanistic insights contributed to tool development at Diamond Light Source and National Synchrotron Light Source II, while academic collaborations with Bill & Melinda Gates Foundation‑funded programs apply enzyme modulation to bioenergy and global health challenges.

Category:Enzymes